Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment-Reference-Cited by-同舟云学术

Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment

Published:2022-04-16 Issue:1 Volume:116 Page:122-130
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Matsue Kosei^ORCID,Sunami Kazutaka,Matsumoto Morio,Kuroda Junya,Sugiura Isamu,Iwasaki Hiromi,Chung Weiyuan,Kuwayama Shigeki,Nishio Mitsufumi,Lee Kim,Iida Shinsuke

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-022-03338-4.pdf

Reference27 articles.

1. Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol. 2017;179:198–218.

2. Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396–406.

3. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67.

4. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–61.

5. Moreau P, Zamagni E, Mateos M-V. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19

2. From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma;Heliyon;2024-05